“Rituximab Added to Chemotherapy Improves Outcomes in High-Risk Japanese Pediatric Mature B-Cell Non-Hodgkin Lymphoma”

https://pubmed.ncbi.nlm.nih.gov/38112205

The addition of rituximab to standard chemotherapy in Japanese children with high-risk mature B-cell non-Hodgkin lymphoma showed promising efficacy and safety outcomes.